Innoviva reported strong growth in its infectious disease and critical care medicines, supported by increasing XACDURO sales and the commercial launch of Nuzolvence. However, a substantial non-cash decline in the value of healthcare investments produced a quarterly net loss despite improving operating profitability.
Summit Therapeutics has secured a $2 billion strategic equity investment from AstraZeneca while expanding the global development programme for ivonescimab. However, the November 14 FDA decision remains uncertain because the original HARMONi overall-survival analysis did not achieve statistical significance, despite favourable results from subsequent analyses and separate Chinese trials.
Evommune is expanding its immunology pipeline through an exclusive licensing agreement for Hinova Pharmaceuticals' investigational oral VAV1 molecular glue degrader. The deal combines $30 million in upfront consideration with more than $1 billion in potential milestone payments, but the drug has not yet demonstrated safety or efficacy in patients.
Oryzon Genomics reports a 95% AML response rate with iadademstat. See the remission findings, survival data and plans for Phase 3 trials.
Idorsia's daridorexant gains FDA breakthrough status after improving sleep in children. Discover Phase 2 findings and upcoming Phase 3 plans.
Oncolytics Biotech reports HPV-specific T-cell responses with pelareorep in anal cancer. See what the new immune findings mean for treatment.
Moleculin Biotech's Annamycin shows 43% leukemia remission as MIRACLE data heads to ASH 2026. See what the early 2027 readout could reveal.
Kairos Pharma has presented interim Phase 2 findings showing substantially longer progression-free survival with ENV-105 plus apalutamide than with apalutamide alone. However, the number of patients in the analysis and key statistical details remain undisclosed, while a redesigned trial will test the treatment earlier in the course of resistance.
Bayer is preparing new analyses spanning stroke prevention, heart failure and chronic kidney disease for AHA Scientific Sessions 2026. The presentations follow China's approval of asundexian and expanding US indications for finerenone, but most of the newly scheduled subgroup findings remain undisclosed.
A prespecified analysis of the SYMPHONY-PE study found encouraging short-term results among women undergoing large-bore aspiration thrombectomy, despite greater cardiac stress at presentation. However, two major bleeding events in women and the absence of a randomised control group highlight the importance of cautious interpretation.